The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis.
Sign Up to like & getrecommendations! Published in 2020 at "Bone"
DOI: 10.1016/j.bone.2020.115478
Abstract: INTRODUCTION In women with postmenopausal osteoporosis denosumab discontinuation is associated with rapid bone loss that could be potentially prevented by a single zoledronate infusion for two years. The longer-term effects, however, of zoledronate treatment are… read more here.
Keywords: bone; zoledronate infusion; year; denosumab discontinuation ... See more keywords
Risk Factors for Denosumab Discontinuation in Patients with Postmenopausal Osteoporosis.
Sign Up to like & getrecommendations! Published in 2022 at "Modern rheumatology"
DOI: 10.1093/mr/roac070
Abstract: OBJECTIVES Persistence with treatment is key to achieving successful treatment outcomes in patients with osteoporosis. We investigated risk factors for denosumab discontinuation in patients with postmenopausal osteoporosis (PMO). METHODS A total of 333 patients with… read more here.
Keywords: factors denosumab; denosumab discontinuation; risk factors; discontinuation patients ... See more keywords
SAT0464 MULTIPLE REBOUND-ASSOCIATED VERTEBRAL FRACTURES AFTER DENOSUMAB DISCONTINUATION IN RHEUMATOLOGY CLINIC
Sign Up to like & getrecommendations! Published in 2020 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2020-eular.660
Abstract: Denosumab, a monoclonal antibody against RANKL, is an effective treatment for osteoporosis. Discontinuation of denosumab has been shown to lead in multiple vertebral fractures in some patients due to a severe acceleration of bone resorption… read more here.
Keywords: vertebral fractures; treatment; rebound associated; discontinuation ... See more keywords